Literature DB >> 11435597

Transcription pattern of human herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma.

P Rimessi1, A Bonaccorsi, M Stürzl, M Fabris, E Brocca-Cofano, A Caputo, G Melucci-Vigo, M Falchi, A Cafaro, E Cassai, B Ensoli, P Monini.   

Abstract

Human herpesvirus 8 (HHV-8) is found in immunoblastic B cells of patients with multicentric Castleman's disease (MCD) and, predominantly in a latent form, in primary effusion lymphoma (PEL) cells and Kaposi's sarcoma (KS) spindle cells. Recent studies have shown that upon reactivation, HHV-8 expresses factors that downregulate major histocompatibility class I proteins and coactivation molecules and that may enable productively infected cells to escape cytotoxic T lymphocytes and natural killer cell responses. One of these viral factors is encoded by open reading frame (ORF) K3. Here we show that in PEL cells, ORF K3 is expressed through viral transcripts that are induced very early upon virus reactivation, including bicistronic RNA molecules containing coding sequences from viral ORFs K3 and 70. Specifically, we found that a bicistronic transcript was expressed in the absence of de novo protein synthesis, thereby identifying a novel HHV-8 immediate-early gene product. Several features of the RNA molecules encoding the K3 product, including multiple transcriptional start sites, multiple donor splicing sites, and potential alternative ATG usage, suggest that there exists a finely tuned modulation of ORF K3 expression. By contrast, ORF K3 transcripts are not detected in the majority of cells present in KS lesions that are latently infected by the virus, suggesting that there are other, as-yet-unknown mechanisms of immune evasion for infected KS spindle cells. Nevertheless, because HHV-8 viremia precedes the development of KS lesions and is associated with the recrudescence of MCD symptoms, the prompt expression of ORF K3 in productively infected circulating cells may be important for virus pathogenesis. Thus, molecules targeting host or viral factors that activate ORF K3 expression or inactivate the biological functions of the K3 product should be exploited for the prevention or treatment of HHV-8-associated diseases in at-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435597      PMCID: PMC114445          DOI: 10.1128/JVI.75.15.7161-7174.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

Authors:  W Zhong; H Wang; B Herndier; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.

Authors:  S J Gao; L Kingsley; D R Hoover; T J Spira; C R Rinaldo; A Saah; J Phair; R Detels; P Parry; Y Chang; P S Moore
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

3.  Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma.

Authors:  M Corbellino; L Poirel; G Bestetti; M Pizzuto; J T Aubin; M Capra; C Bifulco; E Berti; H Agut; G Rizzardini; M Galli; C Parravicini
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-20       Impact factor: 2.205

4.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.

Authors:  L Diatchenko; Y F Lau; A P Campbell; A Chenchik; F Moqadam; B Huang; S Lukyanov; K Lukyanov; N Gurskaya; E D Sverdlov; P D Siebert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients.

Authors:  M Dictor; E Rambech; D Way; M Witte; N Bendsöe
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

6.  Latent BK virus infection and Kaposi's sarcoma pathogenesis.

Authors:  P Monini; A Rotola; L de Lellis; A Corallini; P Secchiero; A Albini; R Benelli; C Parravicini; G Barbanti-Brodano; E Cassai
Journal:  Int J Cancer       Date:  1996-06-11       Impact factor: 7.396

7.  Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma.

Authors:  P S Moore; L A Kingsley; S D Holmberg; T Spira; P Gupta; D R Hoover; J P Parry; L J Conley; H W Jaffe; Y Chang
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

8.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.

Authors:  D Whitby; M R Howard; M Tenant-Flowers; N S Brink; A Copas; C Boshoff; T Hatzioannou; F E Suggett; D M Aldam; A S Denton
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

9.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

10.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

View more
  21 in total

1.  Gammaherpesvirus lytic gene expression as characterized by DNA array.

Authors:  Joo Wook Ahn; Kenneth L Powell; Paul Kellam; Dagmar G Alber
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 2.  Split genes and their expression in Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhi-Ming Zheng
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  Transcriptional analysis of latent and inducible Kaposi's sarcoma-associated herpesvirus transcripts in the K4 to K7 region.

Authors:  Jennifer L Taylor; Heather N Bennett; Beth A Snyder; Patrick S Moore; Yuan Chang
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Jason M Schifano; Kathleen Corcoran; Hemant Kelkar; Dirk P Dittmer
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

6.  Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone.

Authors:  Kevin F Brulois; Heesoon Chang; Amy Si-Ying Lee; Armin Ensser; Lai-Yee Wong; Zsolt Toth; Sun Hwa Lee; Hye-Ra Lee; Jinjong Myoung; Don Ganem; Tae-Kwang Oh; Jihyun F Kim; Shou-Jiang Gao; Jae U Jung
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

7.  Gene structure and expression of Kaposi's sarcoma-associated herpesvirus ORF56, ORF57, ORF58, and ORF59.

Authors:  Vladimir Majerciak; Koji Yamanegi; Zhi-Ming Zheng
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

8.  Redefining the genetics of murine gammaherpesvirus 68 via transcriptome-based annotation.

Authors:  L Steven Johnson; Erin K Willert; Herbert W Virgin
Journal:  Cell Host Microbe       Date:  2010-06-25       Impact factor: 21.023

9.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

10.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.